NAC in CC Resistant PCOS After LOD — NAC  

Clomiphene Citrate Resistant Polycystic Ovary Syndrome Clinical Trial

Official title: N-acetyl-cysteine in Clomiphene Citrate Resistant Polycystic Ovary Syndrome After Laparoscopic Ovarian Drilling: A Randomized Controlled Trial

Status Completed

Clinical Trial Summary

This prospective randomized placebo-controlled double blind clinical trial will conducted in Ain Shams University maternity Hospital including 120 women diagnosed with clomiphene citrate resistant polycystic ovary syndrome. After laparoscopic ovarian drilling, they will be randomized to either receiving 50 mg oral clomiphene citrate twice daily and oral NAC 1,200 mg/day for 5 days starting from cycle day 2 to cycle day 6 (group 1 = 60 patients) or clomiphene citrate only (group 2 = 60 patients). The primary outcome will be biochemical pregnancy rate, secondary outcomes include Clinical pregnancy rate, ovulation rate, live birth rate, number of follicles ≥ 18 mm and endometrial thickness at triggering ovulation, mid- luteal sub-endometrial blood flow indices, and incidence of side effects.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Clomiphene Citrate Resistant Polycystic Ovary Syndrome
• Polycystic Ovary Syndrome
• Syndrome

• NCT number: NCT02775734
• Study type: Interventional
• Source: Ain Shams University
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: May 2016
• Completion date: March 2017